Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …

Statins reduce cholesterol, prevent cardiovascular disease, and are among the most
commonly prescribed medications in the world. Statin‐associated musculoskeletal …

Abstract Purpose of Review The cardiovascular (CV) risk related to lipid disorders is well
established and is based on a robust body of evidence from well-designed randomized …

There is a strong and ever-growing body of evidence regarding the use of
pharmacogenomics to inform cardiovascular pharmacology. However, there is no common …

The value of utilizing a multigene pharmacogenetic panel to tailor pharmacotherapy is
contingent on the prevalence of prescribed medications with an actionable …

Statins, a class of lipid-lowering medications, have been a keystone treatment in
cardiovascular health. However, adverse effects associated with statin use impact patient …

Most of the prescribing and dispensing of medicines happens in primary care.
Pharmacogenomics (PGx) is the study and clinical application of the role of genetic variation …

Conventional medicines optimisation interventions in people with multimorbidity and
polypharmacy are complex and yet limited; a more holistic and integrated approach to …

Background: Adverse drug reactions (ADRs) are a significant cause of mortality, and
pharmacogenomics (PGx) offers the potential to optimize therapeutic efficacy while …

Importance Nonadherence to statin guidelines is common. The solute carrier organic anion
transporter family member 1B1 (SLCO1B1) genotype is associated with simvastatin …